Published on
January 10, 2020
- 00:22 GMT
AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic ...
Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD, in combination with standard PERT for Cystic Fibrosis patients with severe …
Distribution channels:
